Mologic is pleased to announce that the next product to be launched will be an A1AT lateral flow assay.
This will be for the quantitative determination of Alpha-1 antitrypsin (A1AT) concentration in urine and serum samples.
Watch this space for more details.
Mologic is a leading developer of lateral flow and rapid diagnostic technologies, products and services. We work with companies, researchers and clinicians to help them deliver fast, reliable and accurate diagnosis at the point-of-care.
Our Co-founder and Chief Scientific Officer, Paul Davis, was the originator of the Clearblue pregnancy test. Launched in 1988, it was the world’s first commercial application of lateral flow technology. The creativity, insight and knowledge that led to that ground-breaking invention has guided Mologic since our formation in 2003.